Clinical Trial: An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07546110) titled 'An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).' on March 24.

Brief Summary: This is an Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined with NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis

Intervention: BIOLOGICAL: NK042

NK042 is an allogeneic, off-the-shelf cellular therapy derived from healthy donors a...